# A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old

> **NCT02777411** · PHASE2 · COMPLETED · sponsor: **Enimmune Corporation** · enrollment: 122 (actual)

## Conditions studied

- Enterovirus Infections

## Interventions

- **BIOLOGICAL:** EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)
- **BIOLOGICAL:** EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)
- **BIOLOGICAL:** EV71 vaccine ([2 μg total protein + adjuvant 150 μg AIPO4] per dose)
- **BIOLOGICAL:** EV71 vaccine (2 μg total protein per dose)
- **BIOLOGICAL:** EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)
- **BIOLOGICAL:** EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)
- **BIOLOGICAL:** EV71 vaccine (1 μg total protein per dose)

## Key facts

- **NCT ID:** NCT02777411
- **Lead sponsor:** Enimmune Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2016-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02777411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02777411, "A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02777411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*